Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent Reinfection

Gastroenterology

Volumn 138, Issue 1, 2010, Pages 315-324

  Osburn, William O ^a   Fisher, Brian E ^a   Dowd, Kimberly A ^a   Urban, Giselle ^a   Liu, Lin ^b   Ray, Stuart C ^a   Thomas, David L ^a   Cox, Andrea L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CROSS REACTION; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; INFECTION CONTROL; INTRAVENOUS DRUG ABUSE; MALE; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PERSISTENT INFECTION; PRIORITY JOURNAL; REINFECTION; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS PARTICLE;

EID: 72249087933     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.09.017     Document Type: Article

References (30)

1. Cox A., Netski D., Mosbruger T., et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 40 (2005) 951-958
2. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 47 RR-19 (1998) 1-39 Oct 16
3. Garfein R.S., Doherty M.C., Monterroso E.R., et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 18 suppl 1 (1998) S11-S19
4. Villano S.A., Vlahov D., Nelson K.E., et al. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 35 (1997) 3274-3277
5. Hagan H., Thiede H., Weiss N.S., et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 91 (2001) 42-46
6. Hagan H., Pouget E.R., Des Jarlais D.C., et al. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 168 (2008) 1099-1109
7. Cox A.L., Mosbruger T., Lauer G.M., et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42 (2005) 104-112
8. Lanford R.E., Bigger C., Bassett S., et al. The chimpanzee model of hepatitis C virus infections. Ilar J 42 (2001) 117-126
9. Bassett S.E., Guerra B., Brasky K., et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33 (2001) 1479-1487
10. Prince A.M., Brotman B., Lee D.H., et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 192 (2005) 1701-1709
11. Folgori A., Capone S., Ruggeri L., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12 (2006) 190-197
12. Lanford R.E., Guerra B., Chavez D., et al. Cross-genotype immunity to hepatitis C virus. J Virol 78 (2004) 1575-1581
13. Mehta S.H., Cox A., Hoover D.R., et al. Protection against persistence of hepatitis C. Lancet 359 (2002) 1478-1483
14. Grebely J., Conway B., Raffa J., et al. Hepatitis C virus reinfection in injection drug users. Hepatology 44 (2006) 1139-1145
15. Aitken C.K., Lewis J., Tracy S.L., et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 48 (2008) 1746-1752
16. Ray S.C., Arthur R.R., Carella A., et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 182 (2000) 698-707
17. Jeanmougin F., Thompson J.D., Gouy M., et al. Multiple sequence alignment with Clustal X. Trends Biochem Sci 23 (1998) 403-405
18. Los Alamos National Laboratory. HCV phylogenetic placement service. http://hcv.lanl.gov/content/sequence/phyloplace/PhyloPlace.html Accessed June 2009
19. Hsu M., Zhang J., Flint M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100 (2003) 7271-7276
20. Logvinoff C., Major M.E., Oldach D., et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101 (2004) 10149-10154
21. Dowd K.A., Hershow R.C., Yawetz S., et al. Maternal neutralizing antibody and transmission of hepatitis C virus to infants. J Infect Dis 198 (2008) 1651-1655
22. Lechner F., Gruener N.H., Urbani S., et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 30 (2000) 2479-2487
23. Cooper S., Erickson A.L., Adams E.J., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10 (1999) 439-449
24. Dowd K.A., Netski D.M., Wang X.H., et al. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 136 (2009) 2377-2386
25. Thimme R., Oldach D., Chang K.M., et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 (2001) 1395-1406
26. Nascimbeni M., Mizukoshi E., Bosmann M., et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 77 (2003) 4781-4793
27. Shoukry N.H., Grakoui A., Houghton M., et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197 (2003) 1645-1655
28. Keck Z.Y., Li T.K., Xia J., et al. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 82 (2008) 6061-6066
29. Owsianka A.M., Tarr A.W., Keck Z.Y., et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol 89 (2008) 653-659
30. Laskus T., Wang L.F., Radkowski M., et al. Exposure of hepatitis C virus-negative recipients to > or =2 infected blood donors. J Infect Dis 183 (2001) 666-669